

Electronic Supplementary Material (ESI) for Organic &
Biomolecular Chemistry.

This journal is © The Royal Society of Chemistry 2014

**AcOH-mediated dichloroimination of indoles using
chloramine-B: A facile access to 2,3-functionalized indolines**

Xiaozu Liu, Qinghong Hu, Zeli Yuan*, Peijun Liu*

Pharmacy School, Zunyi Medical University, Zunyi, 563000, P. R. China.

Fax: 0086-852-8609493; E-mail: pjliu@zmc.edu.cn, zlyuan@zmc.edu.cn

Electronic Supplementary Information


Content

I . General information.....	S2
II . General procedure for AcOH-mediated dichloroimination of indoles using chloramine-B	S2
III. Procedures for the transformation of indolines 2 to isatin analogs and 2-aminoindoles	S2
IV. Procedures for the syntheses of 8 and 9	S3
V . Experimental data for the described substances	S4
VI. X-ray crystallographic data of 2i	S11
VII. References	S12
VIII. Spectral copies of ¹ H- and ¹³ C-NMR	S12

I. General information

All chemicals were purchased from commercial suppliers and used without further purification. ^1H -NMR and ^{13}C -NMR were recorded on an Agilent 400 MHz spectrometer using TMS as internal standard. Spin multiplicities are given as s (singlet), d (doublet), t (triplet), q (quartet) and m (multiplet) as well as brs (broad). Coupling constants (J) are given in hertz (Hz). High resolution mass spectra were obtained from Applied Biosystems (ABI) Q-Star Elite MALDI-TOF Mass Spectrometer. All experiments were monitored by thin layer chromatography (TLC).


II. General procedure for AcOH-mediated dichloroimination of indoles using chloramine-B



To a stirred mixture of indoles **1** (1.0 mmol) and compound **3** (3.0 mmol) in CH_3CN (10 mL) at 0 °C, AcOH (5.0 mmol) was added. After addition, the reaction mixture was stirred for further 0.5 hour at the same temperature. The reaction mixture was filtered. The filtrate was concentrated in vacuo. Purification of the resulted crude through a flash chromatography on silica gel with petroleum ether/ethyl acetate (v/v = 3/1) afforded the desired product **2**.


III. Procedures for the transformation of indolines **2** to isatin analogs and 2-aminoindoles

1. Procedure for synthesis of **4**




A mixture of **2a** (106.1 mg, 0.3 mmol) in AcOH/ H_2O (9:1, 10 mL) was stirred in a round bottom flask at 45 °C for 6 hours. Removal of the solvent in vacuo and purification of the resulted crude through a flash chromatography on silica gel with petroleum ether/ethyl acetate (v/v = 5/1) afforded the desired product **4** as a brown solid (71.1 mg, 0.24 mmol, 79 %).

2. Procedure for synthesis of **5**



A mixture of **2a** (106.1 mg, 0.3 mmol) in AcOH/H₂O (9:1, 10 mL) in a round bottom flask was refluxed for 4 hours. Removal of solvent in vacuo and purification of the resulted crude through a flash chromatography on silica gel with petroleum ether/ethyl acetate (v/v = 2/1) afforded the desired product **5** as a brown solid (32.4 mg, 0.20 mmol, 67 %).


3. Procedure for synthesis of **6**



To a stirred solution of **2n** (123.6 mg, 0.3 mmol) in MeOH (10 mL) at 0 °C, NaBH₄ (13.7 mg, 0.36 mmol) was added. The reaction mixture was stirred at 0 °C for 30 minutes and quenched with saturated aqueous NH₄Cl solution (5 mL). The resulted mixture was extracted by ethyl acetate (10 mL × 3). The combined organic extracts were washed with brine, dried over MgSO₄, filtered and concentrated in vacuo. Purification of the resulted crude through a flash chromatography on silica gel with petroleum ether/ethyl acetate (v/v = 5/1) to afford the desired product **6** as a white solid (106.6 mg, 0.28 mmol, 94 %).


IV. Procedures for the syntheses of **8** and **9**

1. Synthesis of **8**



To a stirred mixture of **7** (100.0 mg, 0.32 mmol) and chloramine-B (204.1 mg, 0.96 mmol) in CH₃CN (8 mL), AcOH (0.092 mL, 1.6 mmol) was added. The reaction mixture was stirred at 0 °C for further 1 hour. TLC monitoring indicated the substrate **7** was consumed completely. The reaction mixture was filtered. The filtrate was concentrated in vacuo. Purification of the resulted crude through a flash chromatography on silica gel with petroleum ether/ethyl acetate (v/v = 5/1) afforded the desired product **8** as a white solid (82.7 mg, 0.27 mmol, 83%).


2. Synthesis of **9**




A mixture of **7** (62.6 mg, 0.20 mmol), aniline (0.073 mL, 0.80 mmol) and chloramine-B (85.2 mg, 0.4 mmol) in CH₃CN (3 mL) was cooled to 0 °C, followed by addition of AcOH (0.023 mL,

0.4 mmol). The reaction mixture was warming to room temperature and kept stirring for 4 hours. TLC monitoring indicated the substrate **7** was consumed completely. The reaction mixture was filtered. The filtrate was concentrated in vacuo. Purification of the resulted crude through a flash chromatography on silica gel with petroleum ether/ethyl acetate (v/v = 2/1) afforded the desired product **9** as a brown solid (53.5 mg, 0.13 mmol, 66%).


V. Experimental data for the described substances



(*E*)-*N*-(3,3-dichloro-1-methylindolin-2-ylidene)benzenesulfonamide (**2a**). yellow solid, 92% yield. ^1H NMR (400 MHz, CDCl_3) δ 8.10 (d, J = 7.5 Hz, 2H), 7.68 (d, J = 7.6 Hz, 1H), 7.52-7.60 (m, 3H), 7.45 (t, J = 7.8 Hz, 1H), 7.26-7.29 (m, 1H), 6.95 (d, J = 7.9 Hz, 1H), 3.58 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 160.92, 142.69, 140.08, 132.25, 131.92, 131.06, 128.72, 126.74, 125.37, 124.55, 110.00, 31.29. HRMS-ESI (m/z): calcd for $\text{C}_{15}\text{H}_{12}\text{Cl}_2\text{N}_2\text{NaO}_2\text{S}$ $[\text{M}+\text{Na}]^+$: 376.9894, found 376.9905.




(*E*)-*N*-(1-benzyl-3,3-dichloroindolin-2-ylidene)benzenesulfonamide (**2b**). yellow solid, 57% yield. ^1H NMR (400 MHz, CDCl_3) δ 8.02 (d, J = 7.1 Hz, 2H), 7.68 (d, J = 6.9 Hz, 1H), 7.55-7.48 (m, 3H), 7.31-7.19 (m, 7H), 6.82 (d, J = 7.6 Hz, 1H), 5.05 (s, 2H). ^{13}C NMR (100 MHz, CDCl_3) δ 160.59, 142.43, 138.45, 133.69, 132.29, 131.74, 131.47, 129.05, 128.73, 128.23, 127.19, 126.77, 125.27, 124.50, 110.69, 74.65, 46.57. HRMS-ESI (m/z): calcd for $\text{C}_{21}\text{H}_{16}\text{Cl}_2\text{N}_2\text{NaO}_2\text{S}$ $[\text{M}+\text{Na}]^+$: 453.0207, found 453.0220.




(*E*)-*N*-(1-allyl-3,3-dichloroindolin-2-ylidene)benzenesulfonamide (**2c**). brown solid, 79% yield.

^1H NMR (400 MHz, CDCl_3) δ 8.07 (d, J = 7.6 Hz, 2H), 7.68 (d, J = 7.7 Hz, 1H), 7.61-7.47 (m, 3H), 7.40 (t, J = 7.9 Hz, 1H), 7.27-7.21 (m, 1H), 6.91 (d, J = 8.0 Hz, 1H), 5.84 (td, J = 12.6, 10.9, 5.3 Hz, 1H), 5.24 (t, J = 13.7 Hz, 2H), 4.55 (s, 2H). ^{13}C NMR (100 MHz, CDCl_3) δ 160.17, 142.66, 138.83, 132.20, 131.69, 131.35, 129.32, 128.67, 126.72, 125.20, 124.52, 118.93, 110.57, 75.37, 45.76. HRMS-ESI (m/z): calcd for $\text{C}_{17}\text{H}_{14}\text{Cl}_2\text{N}_2\text{NaO}_2\text{S}$ [$\text{M}+\text{Na}$] $^+$: 403.0051, found 403.0061.




2d

(*E*)-*N*-(3,3-dichloro-1,4-dimethylindolin-2-ylidene)benzenesulfonamide (**2d**). yellow solid, 55% yield. ^1H NMR (400 MHz, CDCl_3) δ 8.10 (d, J = 7.2 Hz, 2H), 7.62-7.47 (m, 3H), 7.33 (t, J = 7.9 Hz, 1H), 7.02 (d, J = 7.8 Hz, 1H), 6.79 (d, J = 7.9 Hz, 1H), 3.59 (s, 3H), 2.64 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 160.76, 142.94, 140.57, 136.93, 132.14, 131.64, 128.68, 127.70, 127.32, 126.64, 107.63, 77.58, 31.58, 17.31. HRMS-ESI (m/z): calcd for $\text{C}_{16}\text{H}_{14}\text{Cl}_2\text{N}_2\text{NaO}_2\text{S}$ [$\text{M}+\text{Na}$] $^+$: 391.0051, found 391.0042.



2e


(*E*)-methyl 3,3-dichloro-1-methyl-2-((phenylsulfonyl)imino)indoline-4-carboxylate (**2e**). yellow solid, 52% yield. ^1H NMR (400 MHz, CDCl_3) δ 8.10 (d, J = 7.0 Hz, 2H), 7.85 (d, J = 8.0 Hz, 1H), 7.66-7.45 (m, 4H), 7.18 (d, J = 8.0 Hz, 1H), 4.02 (s, 3H), 3.66 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 164.44, 161.16, 142.69, 141.71, 132.28, 132.10, 129.31, 128.73, 127.95, 127.27, 126.67, 114.01, 52.51, 32.06. HRMS-ESI (m/z): calcd for $\text{C}_{17}\text{H}_{14}\text{Cl}_2\text{N}_2\text{NaO}_4\text{S}$ [$\text{M}+\text{Na}$] $^+$: 434.9949, found 434.9943.




2f

(*E*)-*N*-(3,3-dichloro-1,5-dimethylindolin-2-ylidene)benzenesulfonamide (**2f**). yellow solid, 65% yield. ^1H NMR (400 MHz, CDCl_3) δ 8.09 (d, J = 6.6 Hz, 2H), 7.58-7.50 (m, 3H), 7.22 (s, 1H), 6.95 (d, J = 8.2 Hz, 1H), 6.86 (d, J = 8.6 Hz, 1H), 3.85 (s, 3H), 3.56 (s, 3H). ^{13}C NMR (100 MHz,


CDCl₃) δ 160.78, 157.87, 142.87, 133.24, 132.15, 131.97, 128.69, 126.63, 117.23, 110.97, 110.41, 56.01, 31.53. HRMS-ESI (m/z): calcd for C₁₆H₁₄Cl₂N₂NaO₂S [M+Na]⁺ : 391.0051, found 391.0062.



(*E*)-*N*-(5-bromo-3,3-dichloro-1-methylindolin-2-ylidene)benzenesulfonamide (**2g**). yellow solid, 73% yield. ¹H NMR (400 MHz, CDCl₃) δ 8.07 (d, *J* = 8.1 Hz, 2H), 7.78 (s, 1H), 7.63-7.49 (m, 4H), 6.82 (d, *J* = 8.4 Hz, 1H), 3.53 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 160.30, 142.40, 139.11, 134.75, 132.66, 132.37, 128.74, 127.76, 126.76, 117.85, 111.43, 31.32. HRMS-ESI (m/z): calcd for C₁₅H₁₁BrCl₂N₂NaO₂S [M+Na]⁺ : 454.8999, found 454.8997.




(*E*)-*N*-(1-benzyl-5-bromo-3,3-dichloroindolin-2-ylidene)benzenesulfonamide (**2h**). brown solid, 73% yield. ¹H NMR (400 MHz, CDCl₃) δ 8.02 (d, *J* = 7.2 Hz, 2H), 7.79 (s, 1H), 7.59-7.53 (m, 1H), 7.48-7.45 (m, 2H), 7.42 (d, *J* = 8.2 Hz, 1H), 7.27 (s, 3H), 7.16 (s, 2H), 6.69 (d, *J* = 8.5 Hz, 1H), 5.03 (s, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 159.99, 142.26, 137.57, 134.60, 133.32, 133.06, 132.41, 129.12, 128.77, 128.37, 127.65, 127.13, 126.78, 117.72, 112.28, 73.88, 46.72. HRMS-ESI (m/z): calcd for C₂₁H₁₅BrCl₂N₂NaO₂S [M+Na]⁺ : 530.9312, found 530.9306.




(*E*)-*N*-(1-allyl-5-bromo-3,3-dichloroindolin-2-ylidene)benzenesulfonamide (**2i**). yellow solid, 67% yield. ¹H NMR (400 MHz, CDCl₃) δ 8.05 (d, *J* = 7.4 Hz, 2H), 7.79 (d, *J* = 1.9 Hz, 1H), 7.61-7.44 (m, 4H), 6.80 (d, *J* = 8.4 Hz, 1H), 5.81 (ddd, *J* = 22.4, 10.5, 5.3 Hz, 1H), 5.26 (d, *J* = 10.3 Hz, 1H), 5.20 (d, *J* = 17.2 Hz, 1H), 4.52 (d, *J* = 5.4 Hz, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 159.59, 142.26,

137.78, 134.62, 132.88, 132.43, 128.93, 128.76, 127.70, 126.76, 119.13, 117.72, 112.15, 74.31, 45.75. HRMS-ESI (m/z): calcd for $C_{17}H_{13}BrCl_2N_2NaO_2S$ $[M+Na]^+$: 480.9156, found 480.9167.




2j

(*E*)-*N*-(3,3,5-trichloro-1-methylindolin-2-ylidene)benzenesulfonamide (**2j**). brown solid, 71% yield. 1H NMR (400 MHz, $CDCl_3$) δ 8.07 (d, J = 7.8 Hz, 2H), 7.64 (s, 1H), 7.58-7.50 (m, 3H), 7.40 (d, J = 8.4, 1H), 6.88 (d, J = 6.9 Hz, 1H), 3.53 (s, 3H). ^{13}C NMR (100 MHz, $CDCl_3$) δ 160.38, 142.36, 138.57, 132.25, 131.86, 130.79, 128.70, 126.78, 124.87, 111.09, 75.60, 31.27. HRMS-ESI (m/z): calcd for $C_{15}H_{11}Cl_3N_2NaO_2S$ $[M+Na]^+$: 410.9505, found 410.9500.




2k

(*E*)-*N*-(3,3-dichloro-5-methoxy-1-methylindolin-2-ylidene)benzenesulfonamide (**2k**). yellow solid, 59% yield. 1H NMR (400 MHz, $CDCl_3$) δ 8.09 (d, J = 6.6 Hz, 2H), 7.57-7.50 (m, 3H), 7.22 (s, 1H), 6.96 (d, J = 8.2 Hz, 1H), 6.86 (d, J = 8.6 Hz, 1H), 3.85 (s, 1H), 3.56 (s, 1H). ^{13}C NMR (100 MHz, $CDCl_3$) δ 160.78, 157.87, 142.87, 133.24, 132.15, 131.97, 128.69, 126.63, 117.23, 110.97, 110.41, 56.01, 31.53. HRMS-ESI (m/z): calcd for $C_{16}H_{14}Cl_2N_2NaO_3S$ $[M+Na]^+$: 407.0000, found 406.9997.




2l

(*E*)-*N*-(3,3-dichloro-5-formyl-1-methylindolin-2-ylidene)benzenesulfonamide (**2l**). yellow solid, 85% yield. 1H NMR (400 MHz, $CDCl_3$) δ 10.00 (s, 1H), 8.20 (s, 1H), 8.09 (d, J = 7.9 Hz, 2H), 8.00 (d, J = 8.2 Hz, 1H), 7.63-7.53 (m, 3H), 7.10 (d, J = 8.2 Hz, 1H), 3.57 (s, 3H). ^{13}C NMR (100 MHz, $CDCl_3$) δ 189.68, 160.71, 144.68, 142.05, 134.63, 133.70, 132.60, 132.10, 128.83, 126.86, 125.33, 110.27, 74.63, 31.08. HRMS-ESI (m/z): calcd for $C_{16}H_{12}Cl_2N_2NaO_3S$ $[M+Na]^+$: 404.9843, found 404.9829.




2m

(*E*)-*N*-(3,3-dichloro-5-cyano-1-methylindolin-2-ylidene)benzenesulfonamide (**2m**). yellow solid, 74% yield. ^1H NMR (400 MHz, CDCl_3) δ 8.08 (d, $J = 8.3$ Hz, 2H), 7.94 (s, 1H), 7.76 (d, $J = 8.3$ Hz, 1H), 7.65-7.50 (m, 3H), 7.05 (d, $J = 8.3$ Hz, 1H), 3.54 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 160.19, 143.37, 141.86, 136.47, 132.71, 132.14, 128.87, 128.10, 126.88, 117.60, 110.72, 108.63, 74.12, 31.05. HRMS-ESI (m/z): calcd for $\text{C}_{16}\text{H}_{11}\text{Cl}_2\text{N}_3\text{NaO}_2\text{S}$ $[\text{M}+\text{Na}]^+$: 401.9847, found 401.9835.




2n

(*E*)-methyl 3,3-dichloro-1-methyl-2-((phenylsulfonyl)imino)indoline-5-carboxylate (**2n**). yellow solid, 86% yield. ^1H NMR (400 MHz, CDCl_3) δ 8.34 (s, 1H), 8.17 (d, $J = 8.4$ Hz, 1H), 8.09 (d, $J = 7.5$ Hz, 2H), 7.62-7.52 (m, 3H), 7.00 (d, $J = 8.4$ Hz, 1H), 3.96 (s, 3H), 3.56 (s, 3H). ^{13}C NMR (101 MHz, cdcl_3) δ 165.50, 160.89, 143.51, 142.21, 134.01, 132.51, 131.20, 128.80, 127.28, 126.79, 125.87, 109.84, 75.06, 52.51, 31.10. HRMS-ESI (m/z): calcd for $\text{C}_{17}\text{H}_{14}\text{Cl}_2\text{N}_2\text{NaO}_4\text{S}$ $[\text{M}+\text{Na}]^+$: 434.9949, found 434.9956.




2o


(*E*)-*N*-(3,3-dichloro-1-methyl-2-((phenylsulfonyl)imino)indolin-5-yl)-2,2,2-trifluoroacetamide (**2o**). brown solid, 78% yield. ^1H NMR (400 MHz, CDCl_3) δ 8.17 (s, 1H), 8.08 (d, $J = 8.4$ Hz, 2H), 7.96 (s, 1H), 7.73 (d, $J = 8.6$ Hz, 1H), 7.61-7.52 (m, 3H), 6.97 (d, $J = 8.5$ Hz, 1H), 3.56 (s, 3H). ^{13}C NMR (100 MHz, $\text{DMSO}-d_6$) δ 160.59, 155.07 (q, $J = 37.0$ Hz), 143.00, 137.36, 134.35, 133.05, 130.88, 129.62, 126.56, 125.35, 117.28, 116.12 (q, $J = 287.0$ Hz), 112.66, 76.54, 31.74. HRMS-ESI (m/z): calcd for $\text{C}_{17}\text{H}_{12}\text{Cl}_2\text{F}_3\text{N}_3\text{NaO}_3\text{S}$ $[\text{M}+\text{Na}]^+$: 487.9826, found 487.9804.



(*E*)-*N*-(1-allyl-3,3-dichloro-6-fluorindolin-2-ylidene)benzenesulfonamide (**2p**). yellow solid, 83% yield. ^1H NMR (400 MHz, CDCl_3) δ 8.06 (d, J = 8.4 Hz, 2H), 7.65 (dd, J = 8.5, 5.1 Hz, 1H), 7.61-7.49 (m, 3H), 6.92 (t, J = 8.7 Hz, 1H), 6.64 (d, J = 8.4 Hz, 1H), 5.88-5.78 (m, 1H), 5.29 (d, J = 10.3 Hz, 1H), 5.23 (d, J = 17.2 Hz, 1H), 4.51 (d, J = 4.8 Hz, 2H). ^{13}C NMR (100 MHz, CDCl_3) δ 164.64 (d, J = 250.0 Hz), 160.45, 142.31, 140.59 (d, J = 12.0 Hz), 132.41, 128.94, 128.74, 126.93 (d, J = 3.0 Hz), 126.75, 126.17 (d, J = 11.0 Hz), 119.19, 111.81 (d, J = 24.0 Hz), 99.35 (d, J = 28.0 Hz), 74.51, 45.83. HRMS-ESI (m/z): calcd for $\text{C}_{17}\text{H}_{13}\text{Cl}_2\text{FN}_2\text{NaO}_2\text{S}$ [$\text{M}+\text{Na}$] $^+$: 420.9957, found 420.9937.




(*E*)-*N*-(3,3-dichloro-6-fluoro-1-methylindolin-2-ylidene)benzenesulfonamide (**2q**). yellow solid, 78% yield. ^1H NMR (400 MHz, CDCl_3) δ 8.09 (d, J = 7.0 Hz, 2H), 7.75-7.47 (m, 4H), 7.09-6.86 (m, 1H), 6.68 (d, J = 7.5 Hz, 1H), 3.53 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 164.84 (d, J = 252.1 Hz), 161.16, 142.37, 141.88 (d, J = 11.7 Hz), 132.41, 128.77, 126.78, 126.68 (d, J = 3.0 Hz), 126.23 (d, J = 10.0 Hz), 111.86 (d, J = 23.0 Hz), 98.79 (d, J = 28.0 Hz), 75.57, 31.31. HRMS-ESI (m/z): calcd for $\text{C}_{15}\text{H}_{11}\text{Cl}_2\text{FN}_2\text{NaO}_2\text{S}$ [$\text{M}+\text{Na}$] $^+$: 394.9800, found 394.9791.




(*E*)-*N*-(3-chloro-1,3-dimethylindolin-2-ylidene)benzenesulfonamide (**2r**). yellow solid, 94% yield. ^1H NMR (400 MHz, CDCl_3) δ 8.07 (d, J = 6.8 Hz, 2H), 7.62-7.43 (m, 4H), 7.37 (t, J = 7.7 Hz, 1H), 7.21 (t, J = 7.3 Hz, 1H), 6.94 (d, J = 7.6 Hz, 1H), 3.47 (s, 3H), 2.23 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 166.06, 143.11, 141.05, 133.09, 132.01, 130.32, 128.67, 126.59, 124.84, 123.45,


109.80, 64.72, 30.43, 26.98. HRMS-ESI (m/z): calcd for $C_{16}H_{15}ClN_2NaO_2S$ $[M+Na]^+$: 357.0440, found 357.0423.




(*E*)-*N*-(3,3-dichloro-1-methylindolin-2-ylidene)-4-methylbenzenesulfonamide (**2s**). yellow solid, 65% yield. 1H NMR (400 MHz, $CDCl_3$) δ 7.98 (d, J = 8.2 Hz, 2H), 7.67 (d, J = 7.6 Hz, 1H), 7.45 (t, J = 7.9 Hz, 1H), 7.33 (d, J = 8.0 Hz, 2H), 7.26 (m, 1H), 6.94 (d, J = 7.8 Hz, 1H), 3.57 (s, 3H), 2.44 (s, 3H). ^{13}C NMR (100 MHz, $DMSO-d_6$) δ 160.46, 143.34, 140.32, 140.22, 132.93, 130.51, 130.02, 126.62, 126.03, 124.57, 111.98, 77.00, 31.66, 21.46. HRMS-ESI (m/z): calcd for $C_{16}H_{14}Cl_2N_2NaO_2S$ $[M+Na]^+$: 391.0051, found 391.0057.




(*E*)-*N*-(1-methyl-3-oxoindolin-2-ylidene)benzenesulfonamide (**4**). 1H NMR (400 MHz, $CDCl_3$) δ 8.07 (d, J = 8.2 Hz, 2H), 7.68 (d, J = 7.5 Hz, 1H), 7.61 (t, J = 7.8 Hz, 1H), 7.58-7.48 (m, 3H), 7.17 (t, J = 7.5 Hz, 1H), 6.96 (d, J = 8.0 Hz, 1H), 3.33 (s, 3H). ^{13}C NMR (100 MHz, $CDCl_3$) δ 177.98, 151.44, 151.19, 142.56, 137.94, 132.23, 128.53, 126.93, 126.36, 124.55, 118.20, 110.40, 28.46. HRMS-ESI (m/z): calcd for $C_{15}H_{13}N_2O_3S$ $[M+H]^+$: 301.0647, found 301.0641.




1-Methylindoline-2,3-dione (**5**). 1H NMR (400 MHz, $CDCl_3$) δ 7.62-7.59 (m, 2H), 7.13 (t, J = 7.6 Hz, 1H), 6.89 (d, J = 8.1 Hz, 1H), 3.25 (s, 3H). ^{13}C NMR (100 MHz, $CDCl_3$) δ 183.36, 158.21, 151.43, 138.43, 125.27, 123.84, 117.39, 109.95, 26.21. Spectral data was in agreement with that reported in the literature.¹



Methyl 3-chloro-1-methyl-2-(phenylsulfonamido)-1*H*-indole-5-carboxylate (**6**). ¹H NMR (400 MHz, CDCl₃) δ 8.21 (s, 1H), 8.00 (d, *J* = 8.8 Hz, 1H), 7.74 (d, *J* = 8.5 Hz, 2H), 7.64 (t, *J* = 7.5 Hz, 1H), 7.47 (t, *J* = 7.8 Hz, 2H), 7.36 (d, *J* = 8.8 Hz, 1H), 6.71 (s, 1H), 3.94 (s, 3H), 3.88 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 167.68, 138.49, 136.25, 133.68, 129.23, 127.69, 127.47, 124.68, 122.90, 122.47, 121.46, 109.92, 103.18, 52.09, 30.48. HRMS-ESI (*m/z*): calcd for C₁₇H₁₆ClN₂O₄S [M+H]⁺: 379.0519, found 379.0548.



1-Tosyl-1,2,3,8-tetrahydropyrrolo[2,3-*b*]indole (**8**). ¹H NMR (400 MHz, CDCl₃) δ 8.73 (brs, 1H), 7.58 (d, *J* = 6.6 Hz, 2H), 7.35 (d, *J* = 7.1 Hz, 1H), 7.28-7.21 (m, 3H), 7.14-7.07 (m, 2H), 4.12 (t, *J* = 7.8 Hz, 2H), 2.80 (t, *J* = 6.9 Hz, 2H), 2.37 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 144.64, 141.43, 137.97, 131.72, 129.90, 127.70, 124.07, 120.50, 117.60, 111.81, 109.99, 104.10, 55.69, 23.25, 21.60. HRMS-ESI (*m/z*): calcd for C₁₇H₁₇N₂O₂S [M+H]⁺: 313.1011, found 313.1005.



N-phenyl-1-tosyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-*b*]indol-3a-amine (**9**). ¹H NMR (400 MHz, CDCl₃) δ 7.73 (d, *J* = 7.6 Hz, 2H), 7.29 (d, *J* = 7.9 Hz, 2H), 7.18-7.13 (m, 2H), 6.98 (t, *J* = 7.5 Hz, 2H), 6.76 (t, *J* = 7.4 Hz, 1H), 6.70-6.65 (m, 2H), 6.23 (d, *J* = 8.4 Hz, 2H), 5.65 (s, 1H), 4.92 (s, 1H), 3.80 (br s, 1H), 3.55-3.47 (m, 1H), 3.35-3.28 (m, 1H), 2.47-2.36 (m, 4H), 2.32-2.18 (m, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 148.73, 144.56, 143.70, 135.55, 129.91, 129.79, 129.52, 129.08, 127.20, 123.28, 119.50, 118.34, 114.84, 109.84, 79.10, 73.39, 46.02, 37.79, 21.56. HRMS-ESI (*m/z*): calcd for C₂₃H₂₃N₃NaO₂S [M+Na]⁺: 428.1409, found 428.1403.

VI. X-ray Crystallographic Data of **2i**

Colorless crystals of **2i** suitable for X-ray analysis were obtained by recrystallization from Et₂O/hexane.

Datablock: dj816_0m

Bond precision:	C-C = 0.0127 Å	Wavelength=0.71073
Cell:	a=8.9358(18)	b=9.326(2)
	c=12.002(3)	
	alpha=106.670(3)	beta=101.817(4)
	gamma=93.100(4)	
Temperature:	296 K	

Calculated

Reported

Volume	931.0(4)	931.0(4)
Space group	P -1	P-1
Hall group	-P 1	?
Moiety formula	C ₁₇ H ₁₃ BrCl ₂ N ₂ O ₂ S	?
Sum formula	C ₁₇ H ₁₃ BrCl ₂ N ₂ O ₂ S	C ₁₇ H ₁₃ BrCl ₂ N ₂ O ₂ S
Mr	460.16	460.16
Dx,g cm-3	1.641	1.641
Z	2	2
Mu (mm-1)	2.620	2.620
F000	460.0	460.0
F000'	460.41	
h,k,lmax	10,11,14	10,11,14
Nref	3280	3254
Tmin,Tmax	0.630,0.730	0.650,0.744
Tmin'	0.618	
Correction method= MULTI-SCAN		
Data completeness= 0.992	Theta(max)= 25.000	
R(reflections)= 0.0770(2472)	wR2(reflections)= 0.2417(3254)	
S = 1.045	Npar= 226	





Figure 1. The crystal structure of 2i.

VII. References

1. Esmaeili, A.; Darbanian, M. *Tetrahedron*, 2003, **59**, 5545.


VIII. Spectral copies of ¹H- and ¹³C-NMR







8.11
8.09
7.69
7.67
7.60
7.59
7.57
7.55
7.54
7.52
7.47
7.45
7.43
7.29
7.27
7.26
6.96
6.94



3.58


0.01















2c







2c








2d














2e












2f














2h







2h







2i







2i








2j







2j







2k



— 160.78
— 157.87

— 142.87

— 133.24
— 132.15
— 131.97
— 128.69
— 126.63


— 117.23


— 110.97
— 110.41

— 77.42
— 77.11
— 76.79


— 56.01


— 31.53








21







21











2m










2n







2o







2o





2p





2p



165.89
163.39
160.45

142.31
140.65
140.53
132.41
128.94
128.74
126.95
126.91
126.75
126.23
126.12
119.19
111.93
111.69

99.49
99.21

77.40
77.08
76.76
74.51



45.83










8.10
8.08
7.66
7.65
7.63
7.60
7.58
7.56
7.54
7.52
7.27
6.96
6.95
6.92
6.69
6.67

3.53


0.01











2r








2r













4







4







5







5







6







6






8







8


— 144.64
 — 141.43
 — 137.97
 — 129.90
 — 127.78
 — 127.64
 — 124.07
 — 120.50
 — 117.60
 — 111.81
 — 109.99
 — 104.10
 — 77.36
 — 77.04
 — 76.72
 — 55.69
 — 23.25
 — 21.60





9





9

